RetinalGenix Technologies Inc. (RTGN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US76133Y1055
RetinalGenix Technologies Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| EBIT | -4.32 m USD | -2.42 m USD |
| Net income | -4.32 m USD | -2.43 m USD |
| Diluted EPS – continuing operations | -0.24 USD | -0.13 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About RetinalGenix Technologies Inc.
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
More stocks
- KORAMCO The One REIT (417310.KS)
- Acconeer AB (ACCON.ST)
- NutriBand Inc. (NTRB)
- KNH Enterprise Co Ltd (9919.TW)
- Inoue Rubber (Thailand) Public Company Limited (IRC.BK)
- Articore Group Ltd (ATG.AX)
- Brazilian Critical Minerals Ltd (BCM.AX)
- Grong Sparebank (GRONG.OL)
- Moorim P&P Co Ltd (009580.KS)
- myNEWS Holdings Bhd (5275.KL)
- Advanced Flower Capital Inc. (AFCG)
- M & A EQUITY HOLDINGS BERHAD (7082.KL)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.